According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...
The first dose of the COVID vaccine AZD1222 was associated with an increased risk for thrombotic thrombocytopenia syndrome (TTS) within 28 days after vaccination; however, no significant association ...
Dengue comes with fever, body pain, and a whole lot of confusion, especially when it comes to treatment. The moment someone ...
The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately $75 million for the full year of 2025Autolus ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...
Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback